Bill Brooks, vice president of transportation with Capgemini North America, Inc., lays out the multiple challenges involved in manufacturing, storing and delivering millions of doses of the vaccine for COVID-19 in the coming months.
Daniel Hartnett, associate managing director of the Compliance Risk & Diligence Practice of Kroll, advises on the steps that pharmaceutical companies should take to reduce the risk of dealing with third parties, as they develop a COVID-19 vaccine.
The COVID-19 pandemic has companies across the supply chain seeking efficiencies by cutting team members and increasing automation. But we can’t provide exceptional customer experiences with layoffs and more machines.